
The aim of our study was to investigate the role of electroporation in the treatment of cisplatin resistant tumor cells in vitro. For this purpose we used well characterized human ovarian carcinoma IGROV I cells and their resistant subclone IGROV 1/DDP. The cells were either continuously exposed to cisplatin or treated with electrochemotherapy (exposure time: 5 minutes). After chronic exposure of cells to cisplatin, IGROV 1/DDP cells exhibited 8-fold resistance to cisplatin. Cisplatin cytotoxicity was greatly potentiated by treatment with electric pulses in both cell lines. However, the IGROV 1/DDP cells still exhibited a 50-fold resistance. Our results demonstrate that electroporation treatment potentiates cytotoxicity in both human ovarian carcinoma IGROV 1 cells as well as in their resistant subclone IGROV 1/DDP.
Ovarian Neoplasms, Cell Membrane Permeability, Cell Survival, Drug Resistance, Neoplasm, Tumor Cells, Cultured, Humans, Electric Stimulation Therapy, Female, Cisplatin, Combined Modality Therapy, Clone Cells
Ovarian Neoplasms, Cell Membrane Permeability, Cell Survival, Drug Resistance, Neoplasm, Tumor Cells, Cultured, Humans, Electric Stimulation Therapy, Female, Cisplatin, Combined Modality Therapy, Clone Cells
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 27 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
